Tag: Barostim Neo

CVRx® Completes Enrollment of the BeAT-HF Phase III Randomized Clinical Trial, Continues to collect Morbidity and Mortality Outcomes

CVRx Enrolls the First Patient in a Post Market Heart Failure Registry MINNEAPOLIS, July 21, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced that the BeAT-HF phase III randomized clinical trial has completed enrollment in the post-market phase. CVRx has also enrolled the first patient in a heart failure (“HF”) […]

FDA approves new device to improve symptoms in patients with advanced heart failure

SILVER SPRING, Md., Aug. 16, 2019 /PRNewswire/ — The U.S. Food and Drug Administration today approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other heart failure devices, such as cardiac resynchronization therapy. The FDA gave the device […]